Neurocrine Biosciences Inc
NASDAQ:NBIX

Watchlist Manager
Neurocrine Biosciences Inc Logo
Neurocrine Biosciences Inc
NASDAQ:NBIX
Watchlist
Price: 125.88 USD 0.7% Market Closed
Market Cap: 12.7B USD
Have any thoughts about
Neurocrine Biosciences Inc?
Write Note

Operating Margin
Neurocrine Biosciences Inc

26.2%
Current
18%
Average
-7.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
26.2%
=
Operating Profit
588.3m
/
Revenue
2.2B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Neurocrine Biosciences Inc
NASDAQ:NBIX
12.7B USD
26%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
314.7B USD
28%
US
Amgen Inc
NASDAQ:AMGN
157B USD
19%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD
40%
US
Gilead Sciences Inc
NASDAQ:GILD
112.2B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
133.6B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
34.5B EUR
-22%
Country US
Market Cap 12.7B USD
Operating Margin
26%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 314.7B USD
Operating Margin
28%
Country US
Market Cap 157B USD
Operating Margin
19%
Country US
Market Cap 115.9B USD
Operating Margin
40%
Country US
Market Cap 112.2B USD
Operating Margin
38%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 133.6B AUD
Operating Margin
26%
Country US
Market Cap 82.6B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 34.5B EUR
Operating Margin
-22%
No Stocks Found

Neurocrine Biosciences Inc
Glance View

Market Cap
12.7B USD
Industry
Biotechnology

Neurocrine Biosciences Inc. is a biopharmaceutical company committed to improving the lives of those suffering from neurological and endocrine disorders. Founded in 1992 and based in San Diego, California, Neurocrine has carved out a niche in developing innovative therapies that target complex medical conditions. Its flagship product, Ingrezza (valbenazine), has rapidly gained traction as a leading treatment for tardive dyskinesia, a movement disorder often caused by long-term antipsychotic medication use. This success has propelled the company into the limelight and established it as a key player in the CNS (central nervous system) market. Investors are captivated by Neurocrine’s strong clinical pipeline, promising research partnerships, and an agile operational approach that enable it to adapt swiftly to the evolving landscape of biopharma. The company’s growth story is further enhanced by its commitment to expanding its product portfolio. With therapies in development for conditions such as endometriosis and other hormonal disorders, Neurocrine is not just a one-hit wonder; it is poised to become a powerhouse in the biotech domain. Boasting a robust financial position, the company leverages its research capabilities to identify and bring forward transformative treatments. For investors, Neurocrine represents an opportunity at the intersection of science and compassion, as it continually strives to address unmet medical needs with its innovative solutions. With strong leadership and a dedication to breakthrough therapies, the company stands ready to capitalize on the growing demand for specialized medications within the healthcare landscape.

NBIX Intrinsic Value
142.27 USD
Undervaluation 12%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
26.2%
=
Operating Profit
588.3m
/
Revenue
2.2B
What is the Operating Margin of Neurocrine Biosciences Inc?

Based on Neurocrine Biosciences Inc's most recent financial statements, the company has Operating Margin of 26.2%.